Adicet Bio Ownership
| ACET Stock | USD 0.78 0.01 1.27% |
Shares in Circulation | First Issued 2017-06-30 | Previous Quarter 91 M | Current Value 91 M | Avarage Shares Outstanding 25.6 M | Quarterly Volatility 27.3 M |
Adicet |
Adicet Stock Ownership Analysis
About 69.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.34. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adicet Bio has Price/Earnings To Growth (PEG) ratio of 0.82. The entity recorded a loss per share of 1.33. The firm last dividend was issued on the 16th of September 2020. Adicet Bio had 1:7 split on the 16th of September 2020. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people. For more info on Adicet Bio please contact BA CPA at 650 503 9095 or go to https://www.adicetbio.com.Adicet Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adicet Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adicet Bio backward and forwards among themselves. Adicet Bio's institutional investor refers to the entity that pools money to purchase Adicet Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-12-31 | 916.5 K | D. E. Shaw & Co Lp | 2024-12-31 | 847.1 K | Blackrock Inc | 2024-12-31 | 811.8 K | Two Sigma Advisers, Llc | 2024-12-31 | 794 K | Geode Capital Management, Llc | 2024-12-31 | 767.5 K | Two Sigma Investments Llc | 2024-12-31 | 703.4 K | Stonepine Capital Management Llc | 2024-12-31 | 700 K | Alyeska Investment Group, L.p. | 2024-12-31 | 655.7 K | Rbf Llc | 2024-12-31 | 601.1 K | Orbimed Advisors, Llc | 2024-12-31 | 11.4 M | Tang Capital Management Llc | 2024-12-31 | 8.1 M |
Adicet Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adicet Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adicet Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adicet Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adicet Bio Outstanding Bonds
Adicet Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adicet Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adicet bonds can be classified according to their maturity, which is the date when Adicet Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.